InMed Pharmaceuticals (INM) Earnings Yield: History & Chart

InMed Pharmaceuticals Inc.(INM)

Drug Manufacturers - Specialty & Generic · Vancouver, BC

$1.33Daily change unavailable

Delayed quote: Oct 6, 2026, 3:41 PM EDT

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.

Vancouver, BC

6 employees

www.inmedpharma.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Eric A. Adams Chem.

View full financials

NAME	MARKET CAP	EARNINGS YIELD	TTM	3Y	5Y
InMed Pharmaceuticals Inc. (INM)	$7.31M	N/A	N/A	N/A	N/A
Mangoceuticals, Inc. (MGRX)vs ›	$7.46M	N/A	N/A	N/A	N/A
Skye Bioscience, Inc. (SKYE)vs ›	$7.25M	N/A	179.45%	179.45%	179.45%
NeuroSense Therapeutics Ltd. (NRSN)vs ›	$6.95M	N/A	N/A	N/A	N/A
Longeveron Inc. (LGVN)vs ›	$7.18M	N/A	N/A	N/A	N/A
Quince Therapeutics, Inc. (QNCX)vs ›	$7.63M	N/A	N/A	N/A	N/A
ENDRA Life Sciences Inc. (NDRA)vs ›	$7.74M	N/A	N/A	N/A	N/A
Co-Diagnostics, Inc. (CODX)vs ›	$7.03M	N/A	21.79%	16.65%	16.65%
KALA BIO, Inc. (KALA)vs ›	$6.96M	N/A	N/A	N/A	N/A
CNS Pharmaceuticals, Inc. (CNSP)vs ›	$7.76M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EARNINGS YIELD

TTM

InMed Pharmaceuticals Inc. (INM)

$7.31M

N/A

Mangoceuticals, Inc. (MGRX)vs ›

$7.46M

N/A

Skye Bioscience, Inc. (SKYE)vs ›

$7.25M